In Vitro-In Vivo Correlation of BCNU release using Gliadel~direct R Wafers with Three Drug Loadings and Two Different Thicknesses

摘要

The Gliadel~direct R wafer is a biodegradable polymer based drug delivery system developed by Guilford Pharmaceuticals, Inc. as an adjunct therapy to surgery for the treatment of glioblastoma multiformate. Wafers are implanted into the resection cavity following tumor removal and deliver high concentrations of the chemotherapeutic agent Carmustine (BCNU) directly to the site for an extended period of time. Commercially available Gliadel~direct R consist of 200 mg wafers containing 3.85 percent BCNU which are 14 mm in diameter and approximately 1 mm thick.